British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.

Over 30,000 patients registered in the study since 2001.

NEW REGISTRATIONS AND FOLLOW-UP DATA IS SUBMITTED ONLINE, DIRECTLY IN TO THE SECURE STUDY DATABASE.

To sign up please visit https://bsrbr.org/database/

Eligibility for registration

Diagnosis of Rheumatoid Arthritis
Aged 16 Years or over
Starting eligible biologic treatment

Anti-TNF originators
- adalimumab originator* Humira
- etanercept originator* Enbrel
- infliximab originator* Remicade

Biosimilars
- adalimumab biosimilars Amgevita Hulio Hyrimoz Idacio Imraldi Yuflyma
- rituximab biosimilars Rixathon Ruxience
- etanercept biosimilars Benepali Erezi
- infliximab biosimilars Flixabi Inflectra Remsima IV Remsima SC

Other targeted therapies
- baricitinib Olumiant
tocilizumab RoActemra
certolizumab Cimzia
sarilumab Kevzara
tofacitinib Xeljanz
upadacitinib Rinvoq
- filgotinib Jyseleca

*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

Registration within 6 months of the therapy start date*

Please contact the BSRBR-RA team with any questions
https://bsrbr.org/ 0161 275 1652 biologics.register@manchester.ac.uk
https://twitter.com/BSRBR_RA

Recruiting to BSRBR-RA

V17.1: 29/03/2023